71171-94-3

Usage

InChI:InChI=1/C11H12FNO/c1-11(2)7-14-10(13-11)8-3-5-9(12)6-4-8/h3-6H,7H2,1-2H3

Upstream product

• 343316-37-0 2-(4-fluoro-benzoylamino)-2-methyl-propan-1-ol 
• 30093-99-3 4,4-dimethyl-2-oxazoline 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 129665-83-4 Li(4,4-dimethyl-2-oxazolinyl) 
• 403-43-0 4-fluorobenzoyl chloride 
• 124-68-5 2-Amino-2-methyl-1-propanol 
• 118559-32-3 4,4-dimethyl-2-(tri-n-butylstannyl)-2-oxazoline 
• 15518-10-2 3-amino-2-methyl propan-1-ol 
• 459-57-4 4-fluorobenzaldehyde 
• 104283-70-7 4,4-dimethyl-2-(4-fluorophenyl)oxazoline 
• 352-33-0 1-Chloro-4-fluorobenzene 

Downstream Products

• 98191-74-3 2-(4-fluoro-2-methylthiophenyl)-4,4-dimethyloxazoline 
• 1619256-35-7 2-[4-fluoro-2-(2-methylallyl)phenyl]-4,4-dimethyl-1,3-oxazoline 
• 1619256-36-8 4-fluoro-2-(2-methylallyl)benzaldehyde 
• 1619256-52-8 C₂₀H₁₉FN₂ 
• 1093868-91-7 2-(2-bromo-4-fluorophenyl)-4,4-dimethyl-2-oxazoline 
• 166765-57-7 4-fluoro-2-nicotinoylbenzoic acid 

Relevant academic research and scientific papers

Preparation method of acetylation intermediate of (S)-5-fluoro-3-methylisobenzofuran-3-one

The invention provides a preparation method of an acetylation intermediate of (S)-5-fluoro-3-methylisobenzofuran-3-one. The method comprises the following steps: (1) performing a reaction on a fluoroaromatic compound and a metal organic reagent to obtain

Aerobic C(sp2)-H Hydroxylations of 2-Aryloxazolines: Fast Access to Excited-State Intramolecular Proton Transfer (ESIPT)-Based Luminophores

The direct hydroxylation of 2-aryloxazolines via a deprotonative magnesiation using TMPMgCl·LiCl and subsequent oxidation with molecular oxygen or air as a green oxidant is reported. This method proceeds under mild conditions at room temperature with high regioselectivity and chemoselectivity. The obtained phenols exhibit tunable luminescence properties, induced by excited-state intramolecular proton transfer. This method opens a new opportunity for the sustainable synthesis of luminescent organic molecules.

Secondary Phosphine Oxide Preligands for Palladium-Catalyzed C–H (Hetero)Arylations: Efficient Access to Pybox Ligands

C–H arylations of oxazolines were accomplished with a well-defined palladium catalyst derived from a secondary bisdiamantyl phosphine oxide. The single-component secondary phosphine oxide (SPO)-palladium complex enabled C–H activations with aryl bromides

Directed functionalization of halophenyl-2-oxazolines with TMPMgCl?LiCl

A variety of difunctionalized aryl-2-oxazolines were prepared from the reaction of halophenyl-2-oxazolines and TMPMgCl?LiCl to give an organomagnesium reagent, which was then treated with various electrophiles. The metalation step takes place under mild conditions, and this process al-lows for the isolation of the desired products in good yields. No isomeric or other benzyne-derived products were detected. The influence of the halogen substituents on the acidity of the aromatic hydrogen atoms was evaluated by using density functional theory (DFT) calculations.

Palladium catalyzed intramolecular acylcyanation of alkenes using α-iminonitriles

Reported here is a palladium catalyzed intramolecular acylcyanation of alkenes using α-iminonitriles. Through this method, highly functionalized indanones are synthesized in moderate to high yields using Pd(PPh 3)4, without need for any additional ligands, and a common Lewis acid (ZnCl2). Additionally, the reaction tolerates substitution at various positions on the aromatic ring including electron donating and electron withdrawing groups. This journal is the Partner Organisations 2014.

Analogues of doxanthrine reveal differences between the dopamine D 1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines

Efforts to develop selective agonists for dopamine D1-like receptors led to the discovery of dihydrexidine and doxanthrine, two bioisosteric β-phenyldopamine-type full agonist ligands that display selectivity and potency at D1-like receptors. We report herein an improved methodology for the synthesis of substituted chromanoisoquinolines (doxanthrine derivatives) and the evaluation of several new compounds for their ability to bind to D1- and D2-like receptors. Identical pendant phenyl ring substitutions on the dihydrexidine and doxanthrine templates surprisingly led to different effects on D1-like receptor binding, suggesting important differences between the interactions of these ligands with the D1 receptor. We propose, based on the biological results and molecular modeling studies, that slight conformational differences between the tetralin and chroman-based compounds lead to a shift in the location of the pendant ring substituents within the receptor.

C-H bond arylations and benzylations on oxazol(in)es with a palladium catalyst of a secondary phosphine oxide

An air-stable, well-defined palladium complex derived from secondary phosphine oxide (SPO) (1-Ad)2P(O)H enabled efficient C-H bond functionalizations with ample scope, which set the stage for direct arylations and benzylations of (benz)oxazoles, as well as unprecedented palladium-catalyzed C-H bond arylations on nonaromatic oxazolines.

NEW COMPOUNDS I/418

There is provided compounds of formula I, wherein R1 to R7 have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Synthesis of symmetrical triarylphosphines from aryl fluorides and red phosphorus: Scope and limitations

The reaction of aryl fluorides with phosphide anion, generated in situ from the reduction of red phosphorus by lithium metal in liquid ammonia, gave symmetrical triarylphosphines in fair to good yields. Phosphonodiamide, sulfonamide, 2-oxazolyl, and nitrile groups were stable to the reaction conditions, while nitro and bromo substituents were not. para-Substituted aryl fluorides gave higher yields than meta-substituted aryl fluorides, and ortho-substituted aryl fluorides failed to react.

Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists

PCT No. PCT/IB95/00401 Sec. 371 Date Apr. 9, 1997 Sec. 102(e) Date Apr. 9, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/11920 PCT Pub. Date Apr. 25, 1996This invention relates to novel benzopyran and other benzo-fused leukotriene B4 (LTB4) antagonists and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds or a pharmaceutically acceptable salt thereof, and to methods of using such compounds as LTB4 antagonists. The compounds and the pharmaceutically acceptable salts of this invention inhibit the action of LTB4 and are therefore useful in the treatment of LTB4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruritus and acne, stroke and other forms of reperfuslon injury, graft rejection, autoimmune diseases, asthma, and other conditions where marked neutrophil infiltration occurs.